Sebastiano Mercadante1, Federica Aielli2,3, Claudio Adile4, Patrizia Ferrera5, Alessandro Valle6, Flavio Fusco7, Amanda Caruselli8,9, Claudio Cartoni10, Pizzuto Massimo11, Francesco Masedu12, Marco Valenti13, Giampiero Porzio14,15. 1. Pain Relief and Supportive Care Unit, La Maddalena Cancer Center, Palermo, Italy. terapiadeldolore@lamaddalenanet.it. 2. Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. federica.aielli@univaq.it. 3. "L'Aquila per la Vita" Home Care Unit, L'Aquila, Italy. federica.aielli@univaq.it. 4. Pain Relief and Supportive Care Unit, La Maddalena Cancer Center, Palermo, Italy. claudio.adile@hotmail.it. 5. Pain Relief and Supportive Care Unit, La Maddalena Cancer Center, Palermo, Italy. patriziaferrera@inwind.it. 6. Faro Foundation, Turin, Palermo, Italy. Alessandro.valle@tin.it. 7. Home Care Program, Asp 6, Genoa, Italy. Flavio.Fusco@asl3.liguria.it. 8. Pain Relief and Supportive Care Unit, La Maddalena Cancer Center, Palermo, Italy. amandacaruselli@virgilio.it. 9. Home Care Program, SAMO, Palermo, Italy. amandacaruselli@virgilio.it. 10. Division of Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Home Care Service of the Rome Section of the Italian Association Against Leukemias (RomAIL), Rome, Italy. cartoni@bce.uniroma1.it. 11. Palliative Care Unit, Istituti Clinici di Perfezionamento Hospital, Milan, Italy. massimo.pizzuto@icp.mi.it. 12. Department of Biotechnological and Applied Clinical Sciences, Section of Clinical Epidemiology and Environmental Medicine, University of L'Aquila, L'Aquila, Italy. francesco.masedu@cc.univaq.it. 13. Department of Biotechnological and Applied Clinical Sciences, Section of Clinical Epidemiology and Environmental Medicine, University of L'Aquila, L'Aquila, Italy. marco.valenti@cc.univaq.it. 14. Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. porzio@sctf.it. 15. "L'Aquila per la Vita" Home Care Unit, L'Aquila, Italy. porzio@sctf.it.
Abstract
BACKGROUND: Oral symptoms can be a sign of an underlying systemic condition and have a significant impact on quality of life, nutrition, and cost of care, while these lesions are often studied in the context of cancer treatment. However, information regarding oral symptoms in advanced cancer patients is poor. The aim of this multicenter study was to determine the prevalence and the characteristics of oral symptoms in a large population of advanced cancer patients. METHODS: A consecutive sample of patients with advanced cancer for a period of 6 months was prospectively assessed for an observational study. At time of admission, the epidemiological characteristics, surgery-radiotherapy of head and neck, and oncologic treatments in the last month were recorded. The presence of mucositis, dry mouth, and dysphagia was assessed by clinical examination and patients' report and their intensity recorded. Patients were also asked whether they had limitation on nutrition of hydration due to the local condition. RESULTS: Six hundred sixty-nine patients were surveyed in the period taken into consideration. The mean age was 72.1 years (SD 12.3), and 342 patients were males. The primary tumors are listed in Table 1. The prevalence of mucositis was 22.3 %. The symptom relevantly reduced the ingestion of food or fluids and was statistically associated with the Karnofsky level and head and neck cancer. The prevalence of dry mouth was 40.4 %, with a mean intensity of 5.4 (SD 2.1). Several drugs were concomitantly given, particularly opioids (78 %), corticosteroids (75.3 %), and diuretics (70.2 %). Various and nonhomogeneous treatments were given for dry mouth, that was statistically associated with current or recent chemotherapy, and hematological tumors. The prevalence of dysphagia was 15.4 % with a mean intensity of 5.34 (SD 3). Dysphagia for liquids was observed in 52.4 % of cases. A high level of limitation for oral nutrition due to dysphagia was found, and in 53.4 % of patients, alternative routes to the oral one were used. Dysphagia was statistically associated with the Karnofsky level and head and neck cancer. A strong relationship between the three oral symptoms was found. CONCLUSION: In advanced cancer patients, a range of oral problems significantly may impact on the physical, social, and psychological well-being of advanced cancer patients to varying degrees. These symptoms should be carefully assessed early but become imperative in the palliative care setting when they produce relevant consequences that may be life-threatening other than limiting the daily activities, particularly eating and drinking.
BACKGROUND: Oral symptoms can be a sign of an underlying systemic condition and have a significant impact on quality of life, nutrition, and cost of care, while these lesions are often studied in the context of cancer treatment. However, information regarding oral symptoms in advanced cancerpatients is poor. The aim of this multicenter study was to determine the prevalence and the characteristics of oral symptoms in a large population of advanced cancerpatients. METHODS: A consecutive sample of patients with advanced cancer for a period of 6 months was prospectively assessed for an observational study. At time of admission, the epidemiological characteristics, surgery-radiotherapy of head and neck, and oncologic treatments in the last month were recorded. The presence of mucositis, dry mouth, and dysphagia was assessed by clinical examination and patients' report and their intensity recorded. Patients were also asked whether they had limitation on nutrition of hydration due to the local condition. RESULTS: Six hundred sixty-nine patients were surveyed in the period taken into consideration. The mean age was 72.1 years (SD 12.3), and 342 patients were males. The primary tumors are listed in Table 1. The prevalence of mucositis was 22.3 %. The symptom relevantly reduced the ingestion of food or fluids and was statistically associated with the Karnofsky level and head and neck cancer. The prevalence of dry mouth was 40.4 %, with a mean intensity of 5.4 (SD 2.1). Several drugs were concomitantly given, particularly opioids (78 %), corticosteroids (75.3 %), and diuretics (70.2 %). Various and nonhomogeneous treatments were given for dry mouth, that was statistically associated with current or recent chemotherapy, and hematological tumors. The prevalence of dysphagia was 15.4 % with a mean intensity of 5.34 (SD 3). Dysphagia for liquids was observed in 52.4 % of cases. A high level of limitation for oral nutrition due to dysphagia was found, and in 53.4 % of patients, alternative routes to the oral one were used. Dysphagia was statistically associated with the Karnofsky level and head and neck cancer. A strong relationship between the three oral symptoms was found. CONCLUSION: In advanced cancerpatients, a range of oral problems significantly may impact on the physical, social, and psychological well-being of advanced cancerpatients to varying degrees. These symptoms should be carefully assessed early but become imperative in the palliative care setting when they produce relevant consequences that may be life-threatening other than limiting the daily activities, particularly eating and drinking.
Authors: Sarika Hanchanale; Lucy Adkinson; Sunitha Daniel; Michelle Fleming; Stephen G Oxberry Journal: Support Care Cancer Date: 2014-10-18 Impact factor: 3.603
Authors: Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg Journal: Radiother Oncol Date: 2003-03 Impact factor: 6.280
Authors: Bridget Gwilliam; Vaughan Keeley; Chris Todd; Matthew Gittins; Chris Roberts; Laura Kelly; Stephen Barclay; Patrick C Stone Journal: BMJ Date: 2011-08-25
Authors: Miriam O Ezenwa; Dena J Fischer; Joel Epstein; Julie Johnson; Yingwei Yao; Diana J Wilkie Journal: Support Care Cancer Date: 2016-06-29 Impact factor: 3.603
Authors: Colin Lavigne; Harold Lau; George Francis; S Nicole Culos-Reed; Guillaume Y Millet; Rosie Twomey Journal: Eur J Appl Physiol Date: 2020-04-06 Impact factor: 3.078
Authors: Leen Van den Steen; Olivier Vanderveken; Jan Vanderwegen; Dirk Van Gestel; Jean-François Daisne; Johan Allouche; Laurence Delacroix; Diane Van Rompaey; Sylvie Beauvois; Sophie Cvilic; Steven Mariën; Gauthier Desuter; Jan Baptist Vermorken; Danielle Van den Weyngaert; Pol Specenier; Carl Van Laer; Marc Peeters; Paul Van de Heyning; Gilbert Chantrain; Georges Lawson; Cathy Lazarus; Marc De Bodt; Gwen Van Nuffelen Journal: Support Care Cancer Date: 2017-06-02 Impact factor: 3.603
Authors: Barbara Ebersole; Miriam Lango; John Ridge; Elizabeth Handorf; Jeffrey Farma; Sarah Clark; Nausheen Jamal Journal: Otolaryngol Head Neck Surg Date: 2019-12-03 Impact factor: 3.497